Abstract
Epidemiological data have demonstrated a strong relationship between blood pressure (BP) and cardiovascular disease (CVD) risk and have shown the importance of systolic BP (SBP) as a determinant of such risk. The importance of BP as a risk factor has been further emphasized by a World Health Organization (WHO) report which identified high BP as one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. There is now data available on the safety and effectiveness of different classes of BP-lowering drugs, including diuretics, angiotensin-converting enzyme inhibitors (ACE-Is), dihydropyridine and non-dihydropyridine calcium channel blockers (CCBs), beta-blockers and angiotensin receptor blockers (ARBs). In this review we discuss classification of BP stages, goal of therapy, lifestyle modifications and optimal BP control in individual patients. The detection and optimal treatment of hypertension is likely to significantly ameliorate CVD risk.
Cardiovascular & Hematological Disorders-Drug Targets
Title: Contemporary Management of Hypertension - How to Optimize Therapy
Volume: 9 Issue: 3
Author(s): Steve Leung and Debabrata Mukherjee
Affiliation:
Abstract: Epidemiological data have demonstrated a strong relationship between blood pressure (BP) and cardiovascular disease (CVD) risk and have shown the importance of systolic BP (SBP) as a determinant of such risk. The importance of BP as a risk factor has been further emphasized by a World Health Organization (WHO) report which identified high BP as one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. There is now data available on the safety and effectiveness of different classes of BP-lowering drugs, including diuretics, angiotensin-converting enzyme inhibitors (ACE-Is), dihydropyridine and non-dihydropyridine calcium channel blockers (CCBs), beta-blockers and angiotensin receptor blockers (ARBs). In this review we discuss classification of BP stages, goal of therapy, lifestyle modifications and optimal BP control in individual patients. The detection and optimal treatment of hypertension is likely to significantly ameliorate CVD risk.
Export Options
About this article
Cite this article as:
Leung Steve and Mukherjee Debabrata, Contemporary Management of Hypertension - How to Optimize Therapy, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187152909789007061
DOI https://dx.doi.org/10.2174/187152909789007061 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Foot Injuries Among Hajj Pilgrims with and Without Diabetes Mellitus: Implications for Infection Management
Infectious Disorders - Drug Targets Design of a Genetically Modified Soybean Protein Preventing Hypertension Based on an Anti-Hypertensive Peptide Derived from Ovalbumin
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Current Signal Transduction Therapy Skeletal Muscle Protein Balance and Metabolism in the Elderly
Current Aging Science Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Insulin Sensitivity is Modified by a Glycogen Phosphorylase Inhibitor: Glucopyranosylidene-Spiro-Thiohydantoin in Streptozotocin-Induced Diabetic Rats
Current Topics in Medicinal Chemistry Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Mini-Reviews in Medicinal Chemistry Molecular Mapping and Docking Interactions for Selective Anti-Fertility Potency of Estrogen Analogs
Letters in Drug Design & Discovery Characterization of Mitogen-Activated Protein Kinase Expression in Nucleus Accumbens and Hippocampus of Rats Subjected to Food Selection in the Cafeteria Diet Protocol
CNS & Neurological Disorders - Drug Targets Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Modulation of Angiotensin II Effects, A Potential Novel Approach to Inflammatory and Immune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial [Hot Topic: Metabolic Syndrome in an Asian Chinese Population and Agents and Targets for Cardiovascular Protection (Guest Editors: M.L. Fung and T.M. Wong)]
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Hypertension in the Perioperative Period-Focus on Current and Emerging Therapies
Recent Patents on Cardiovascular Drug Discovery Marine-Derived Bioactive Peptides as New Anticoagulant Agents: A Review
Current Protein & Peptide Science Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Resveratrol and Stroke: from Chemistry to Medicine
Current Neurovascular Research Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a<sup>-/-</sup> Model
Current Pharmaceutical Design